Bai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bai Li has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Chunguang Li
Department of Thoracic Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, China
1 shared publicationQijue Lu
Department of Thoracic Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, China
1 shared publicationQuan Chen
Department of Traditional Chinese Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China
1 shared publicationXiang Fei
Department of Thoracic Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 18 October 2021
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 16 (1) , 1-7
Elevated tumor markers in a benign lung disease
Background: This study aimed to determine the underlying pathophysiologic mechanism of elevated carbohydrate antigen 19-9 (CA19-9) in pulmonary sequestration (PS) patients. Materials and methods: Four pulmonary sequestration patients, 12 pneumonia patients and 12 healthy adult volunteers were prospectively studied. Specimens from another 34 pulmonary sequestration patients were retrospectively analyzed. Serum CA19-9 levels of 4 patients were tested before and 1 week, 1 month and 3 months after surgery. The CA19-9 levels of 12 pneumonia patients and 12 healthy adult volunteers were tested as controls. The expression and localization of CA19-9 in diseased lesions and corresponding normal lung tissues were analyzed by Immunohistochemical (IHC). Hematoxylin–eosin (HE) staining was performed to observe the pathological changes in pulmonary sequestration tissues. Results: Serum CA19-9 levels were significantly higher in the 4 patients (797.3 ± 316 IU/ml) than in the pneumonia patients (10.07 ± 5.01 IU/ml) and healthy volunteers (9.85 ± 4.12 IU/ml). In addition, serum CA19-9 levels decreased dramatically after the focus was removed. Positive staining of CA19-9 was found in 70% (24/34) of pulmonary sequestration tissues, and CA19-9 was mainly expressed in the bronchial mucus. In the 4 diseased lesions, deformed alveolar structure and inflammatory cell infiltration were observed, and the degree of damage was positively correlated with serum CA19-9 levels. Conclusions: CA19-9 could be generated by abnormal columnar epithelia in pulmonary sequestration tissues and was transported into circulation after alveoli damage. CA19-9 could serve as an adjuvant diagnostic marker in pulmonary sequestration.
- 18 October 2021
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 16 (1) , 1-7
Open AccessElevated tumor markers in a benign lung disease
Background: This study aimed to determine the underlying pathophysiologic mechanism of elevated carbohydrate antigen 19-9 (CA19-9) in pulmonary sequestration (PS) patients. Materials and methods: Four pulmonary sequestration patients, 12 pneumonia patients and 12 healthy adult volunteers were prospectively studied. Specimens from another 34 pulmonary sequestration patients were retrospectively analyzed. Serum CA19-9 levels of 4 patients were tested before and 1 week, 1 month and 3 months after surgery. The CA19-9 levels of 12 pneumonia patients and 12 healthy adult volunteers were tested as controls. The expression and localization of CA19-9 in diseased lesions and corresponding normal lung tissues were analyzed by Immunohistochemical (IHC). Hematoxylin–eosin (HE) staining was performed to observe the pathological changes in pulmonary sequestration tissues. Results: Serum CA19-9 levels were significantly higher in the 4 patients (797.3 ± 316 IU/ml) than in the pneumonia patients (10.07 ± 5.01 IU/ml) and healthy volunteers (9.85 ± 4.12 IU/ml). In addition, serum CA19-9 levels decreased dramatically after the focus was removed. Positive staining of CA19-9 was found in 70% (24/34) of pulmonary sequestration tissues, and CA19-9 was mainly expressed in the bronchial mucus. In the 4 diseased lesions, deformed alveolar structure and inflammatory cell infiltration were observed, and the degree of damage was positively correlated with serum CA19-9 levels. Conclusions: CA19-9 could be generated by abnormal columnar epithelia in pulmonary sequestration tissues and was transported into circulation after alveoli damage. CA19-9 could serve as an adjuvant diagnostic marker in pulmonary sequestration.